[go: up one dir, main page]

AU2003248708A1 - Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation - Google Patents

Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation

Info

Publication number
AU2003248708A1
AU2003248708A1 AU2003248708A AU2003248708A AU2003248708A1 AU 2003248708 A1 AU2003248708 A1 AU 2003248708A1 AU 2003248708 A AU2003248708 A AU 2003248708A AU 2003248708 A AU2003248708 A AU 2003248708A AU 2003248708 A1 AU2003248708 A1 AU 2003248708A1
Authority
AU
Australia
Prior art keywords
oligomeric compounds
include carbocyclic
gene modulation
carbocyclic nucleosides
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003248708A
Inventor
Balkrishen Bhat
Neelima Bhat
Prasad Dande
Anne B. Eldrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2003248708A1 publication Critical patent/AU2003248708A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003248708A 2002-06-17 2003-06-17 Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation Abandoned AU2003248708A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38916102P 2002-06-17 2002-06-17
US60/389,161 2002-06-17
US42376002P 2002-11-05 2002-11-05
US60/423,760 2002-11-05
PCT/US2003/019043 WO2003106477A1 (en) 2002-06-01 2003-06-17 Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation

Publications (1)

Publication Number Publication Date
AU2003248708A1 true AU2003248708A1 (en) 2003-12-31

Family

ID=29740106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248708A Abandoned AU2003248708A1 (en) 2002-06-17 2003-06-17 Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation

Country Status (2)

Country Link
AU (1) AU2003248708A1 (en)
WO (1) WO2003106477A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
PT1633766T (en) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN110003216A (en) 2006-02-02 2019-07-12 千禧药品公司 E1 activating enzyme inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
NZ580712A (en) 2007-05-22 2011-12-22 Marina Biotech Inc Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers
TW201434851A (en) 2007-08-02 2014-09-16 Millennium Pharm Inc Process for the synthesis of E1 activating enzyme inhibitors
EP2217705A2 (en) * 2007-11-05 2010-08-18 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases in hybridization of nucleic acids
US20110171287A1 (en) * 2007-11-05 2011-07-14 Baltic Technology Develpment, Ltd. Use of Oligonucleotides with Modified Bases as Antiviral Agents
WO2009144365A1 (en) * 2008-05-30 2009-12-03 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
WO2010065756A2 (en) * 2008-12-03 2010-06-10 Mdrna, Inc. Usirna complexes
PA8855601A1 (en) 2008-12-23 2010-07-27 NUCLEOSID FORFORMIDATES
BRPI0922508A8 (en) 2008-12-23 2016-01-19 Pharmasset Inc NUCLEOSID ANALOGS
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
UA108986C2 (en) 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Hydrochloride crystalline form ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ilamino]-7h-pirolo[2,3-d]pyrimidin-7il}-2-hydroxycyclopentil)methyl-sulphamate(configurations)
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
CA2794671C (en) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
CN107365339A (en) 2011-07-19 2017-11-21 波涛生命科学有限公司 Methods of Synthesizing Functionalized Nucleic Acids
KR20190075142A (en) 2011-09-16 2019-06-28 길리애드 파마셋 엘엘씨 Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
RU2693381C2 (en) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Asymmetric auxiliary group
BR112015000723A2 (en) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd chiral nucleic acid adjuvant
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
CN103387587B (en) * 2013-01-14 2015-12-09 重庆康施恩化工有限公司 Entecavir midbodies and preparation method thereof
HUE047777T2 (en) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
PT3094728T (en) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Chiral design
CA2946719C (en) 2014-03-25 2023-09-26 Arcturus Therapeutics, Inc. Una oligomers having reduced off-target effects in gene silencing
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
EP3122365B1 (en) 2014-03-25 2023-05-03 Arcturus Therapeutics, Inc. Transthyretin allele selective una oligomers for gene silencing
EP3277289A4 (en) 2015-04-01 2018-12-05 Arcturus Therapeutics, Inc. Therapeutic una oligomers and uses thereof
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9063398A (en) * 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues

Also Published As

Publication number Publication date
WO2003106477A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
AU2003248708A1 (en) Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
AU2003291755A1 (en) Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
SG10201705641SA (en) Genetic products differentially expressed in tumors and the use thereof
AU2003239129A1 (en) Methods and compositions for dna manipulation
HUP0301063A3 (en) Benzoic-acid isononylesters and applying them
AU2002364051A1 (en) Anti-cancer combination and use thereof
AU2003291751A1 (en) Non-phosphorous-linked oligomeric compounds and their use in gene modulation
AU2003220387A1 (en) Gene amplification in cancer
PL373384A1 (en) Genetic products differentially expressed in tumors and use thereof
AU2003291721A1 (en) Phosphorous-linked oligomeric compounds and their use in gene modulation
AU2003290573A1 (en) Cross-linked oligomeric compounds and their use in gene modulation
AU2003287503A1 (en) Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
AU2003252057A1 (en) Oligomeric dyes and use thereof
AU2003287504A1 (en) Modified oligomeric compounds and compositions for use in gene modulation
AU2003242405A1 (en) Compounds and preparaitons having antiviral effect
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003239589A1 (en) Eta-1 gene and methods for use
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003235096A1 (en) Novel protein and dna thereof
AU2003902983A0 (en) Viral polymerase and modulation thereof
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF
AU2003219732A1 (en) Oligomeric molecules and uses thereof
AU2003258658A1 (en) Improved dna and proteins
AU2003262080A1 (en) Novel protein and dna thereof
AU2003211562A1 (en) Novel dna and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase